A Phase 3 interventional study of Sonazoid™ and SonoVue® in Liver Lesions, sponsored by GE Healthcare. Completed at 18 sites in 3 countries. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-10-31.
Sponsored by GE Healthcare · Phase 3, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to compare the efficacy of Sonazoid™ and SonoVue® in participants with focal liver lesions (FLLs), by comparing pre-and post-contrast ultrasound examination findings with regard to various aspects of lesion diagnosis including diagnosis as benign versus malignant, specific lesion diagnosis, confidence in diagnosis, and quality of delineation of lesion-related blood vessels (from images obtained during vascular imaging) and detection of lesion presence and quality of delineation of the whole liver (from images obtained during whole liver imaging).
GE Healthcare is the lead sponsor of 176 studies on the registry; 21 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 16 (84%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria: Participants may be included in the study if they meet all of the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive single intravenous (I.V) bolus injection of Sonazoid™ 0.12 microliter (µL) microbubbles (MB)/kilogram (kg) body weight.
Drug: Sonazoid™
Participants will receive single I.V bolus injection of SonoVue® 2.4 milliliter (mL).
Drug: SonoVue®
Percentage of Participants With Accuracy Improvement in Post-Contrast Versus Pre-Contrast Ultrasound (US) Examination for Diagnosis of the Target Lesion as Malignant or Benign Against the Reference Diagnosis (RD)/Standard of Truth
Accuracy improvement was calculated by the number of participants with improved diagnoses from the pre-contrast diagnosis to the post-contrast diagnosis divided by the total number of participants, multiplied by 100. Assessments were done by 3 blinded readers. Efficacy population which included all participants who received Sonazoid™ or SonoVue®, for whom pre-contrast \& post-contrast images were recorded, \& for whom there was a reference standard contrast-enhanced computed tomography (CECT)/contrast-enhanced magnetic resonance imaging (CE-MRI) examination or biopsy.
Time frame: Pre-administration up to 15 minutes post-administration
Number of Lesions Detected by Post-Contrast US Relative to Number of Lesions Detected by Pre-Contrast US (Both by Blinded Readers[BR]) and Number of Lesions Detected by Post-Contrast US (by BR) Relative to Number of Lesions Detected by RD (Investigators)
For the cases that can be assessed by the blinded readers both pre- and post-contrast, differences were calculated between the Sonazoid™ and SonoVue® groups in the number of lesions detected during whole-liver imaging (post-contrast minus pre-contrast). The differences were also calculated between the Sonazoid™ and SonoVue® groups in the number of lesions (post-contrast minus reference diagnosis) detected during whole-liver imaging.
Time frame: Pre-administration up to 15 minutes post-administration
Number of Participants With Diagnostic Confidence (Evaluated by Blinded Readers) in Pre-Contrast and Post-Contrast Ultrasound Examination Results
Confidence in diagnoses from the pre- and post-contrast ultrasound examinations was evaluated based on 4-point scale: 0-Unknown (cannot make a judgement on level of confidence), 1- Not confident (another examination was required), 2- Probable (Would have more confidence if another diagnostic imaging test such as MRI or CT was performed), 3- Definite (Sufficient confidence to the extent that another diagnostic imaging test such as MRI or CT was unnecessary).
Time frame: Pre-administration up to 15 minutes post-administration
Percentage of Participants With Accuracy Improvement in Post-contrast Versus Pre-contrast Ultrasound Examination for Lesion-Specific Diagnoses of the Target Lesion Against the Reference Diagnosis/Standard of Truth
The accuracy improvement was calculated by the number of participants with improved diagnoses from the pre-contrast diagnosis to the post-contrast diagnosis divided by the total number of participants, multiplied by 100. Assessment was performed by 3 blinded readers.
Time frame: Pre-administration up to 15 minutes post-administration
The study was conducted at 17 centres in China, Korea and Taiwan. A total of 424 participants were enrolled between 11 May 2014 and 9 April 2015.
| Milestone | Sonazoid™ | SonoVue® |
|---|---|---|
| Started | 218 | 206 |
| Completed | 214 | 203 |
| Not completed | 4 | 3 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Technical problems | 1 | 0 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Other than specified above | 1 | 2 |
Accuracy improvement was calculated by the number of participants with improved diagnoses from the pre-contrast diagnosis to the post-contrast diagnosis divided by the total number of participants, multiplied by 100. Assessments were done by 3 blinded readers. Efficacy population which included all participants who received Sonazoid™ or SonoVue®, for whom pre-contrast \& post-contrast images were recorded, \& for whom there was a reference standard contrast-enhanced computed tomography (CECT)/contrast-enhanced magnetic resonance imaging (CE-MRI) examination or biopsy.
| percentage of participants | Sonazoid™ | SonoVue® |
|---|---|---|
| Reader 1 | 18.1 | 24.2 |
| Reader 2 | 22.1 | 14.6 |
| Reader 3 | 17.0 | 16.7 |
For the cases that can be assessed by the blinded readers both pre- and post-contrast, differences were calculated between the Sonazoid™ and SonoVue® groups in the number of lesions detected during whole-liver imaging (post-contrast minus pre-contrast). The differences were also calculated between the Sonazoid™ and SonoVue® groups in the number of lesions (post-contrast minus reference diagnosis) detected during whole-liver imaging.
| Lesions | Sonazoid™ | SonoVue® |
|---|---|---|
| Post-contrast minus Pre-contrast: Reader 1 | 0.0 (-1.0 to 1.0) | 0.0 (-1.0 to 0.0) |
| Post-contrast minus Pre-contrast: Reader 2 | 0.0 (-2.0 to 0.0) | -1.0 (-2.0 to 0.0) |
| Post-contrast minus Pre-contrast: Reader 3 | 0.0 (-1.0 to 0.0) | -1.0 (-2.0 to 0.0) |
| Post-contrast minus Reference: Reader 1 | 1.0 (0.0 to 2.0) | 1.0 (0.0 to 1.0) |
| Post-contrast minus Reference: Reader 2 | 0.0 (0.0 to 1.0) | 0.0 (0.0 to 0.0) |
| Post-contrast minus Reference: Reader 3 | 0.0 (0.0 to 1.0) | 0.0 (-1.0 to 1.0) |
Confidence in diagnoses from the pre- and post-contrast ultrasound examinations was evaluated based on 4-point scale: 0-Unknown (cannot make a judgement on level of confidence), 1- Not confident (another examination was required), 2- Probable (Would have more confidence if another diagnostic imaging test such as MRI or CT was performed), 3- Definite (Sufficient confidence to the extent that another diagnostic imaging test such as MRI or CT was unnecessary).
| Participants | Sonazoid™ | SonoVue® |
|---|---|---|
| Reader 1: Pre-contrast — Definite (3 points) | 10 | 11 |
| Reader 1: Pre-contrast — Probable (2 points) | 113 | 122 |
| Reader 1: Pre-contrast — Not confident (1 point) | 46 | 36 |
| Reader 1: Pre-contrast — Unknown (0 points) | 0 | 0 |
| Reader 1: Post Contrast — Definite (3 points) | 57 | 54 |
| Reader 1: Post Contrast — Probable (2 points) | 86 | 88 |
| Reader 1: Post Contrast — Not confident (1 point) | 17 | 15 |
| Reader 1: Post Contrast — Unknown (0 points) | 0 | 0 |
| Reader 2: Pre-contrast — Definite (3 points) | 15 | 12 |
| Reader 2: Pre-contrast — Probable (2 points) | 89 | 79 |
| Reader 2: Pre-contrast — Not confident (1 point) | 65 | 78 |
| Reader 2: Pre-contrast — Unknown (0 points) | 0 | 0 |
| Reader 2: Post-contrast — Definite (3 points) | 116 | 103 |
| Reader 2: Post-contrast — Probable (2 points) | 43 | 51 |
| Reader 2: Post-contrast — Not confident (1 point) | 4 | 4 |
| Reader 2: Post-contrast — Unknown (0 points) | 0 | 0 |
| Reader 3: Pre-contrast — Definite (3 points) | 38 | 36 |
| Reader 3: Pre-contrast — Probable (2 points) | 89 | 90 |
| Reader 3: Pre-contrast — Not confident (1 point) | 42 | 42 |
| Reader 3: Pre-contrast — Unknown (0 points) | 0 | 1 |
| Reader 3: Post-contrast — Definite (3 points) | 130 | 117 |
| Reader 3: Post-contrast — Probable (2 points) | 31 | 36 |
| Reader 3: Post-contrast — Not confident (1 point) | 4 | 9 |
| Reader 3: Post-contrast — Unknown (0 points) | 0 | 0 |
The accuracy improvement was calculated by the number of participants with improved diagnoses from the pre-contrast diagnosis to the post-contrast diagnosis divided by the total number of participants, multiplied by 100. Assessment was performed by 3 blinded readers.
| percentage of participants | Sonazoid™ | SonoVue® |
|---|---|---|
| Reader 1 | 11.9 | 21.7 |
| Reader 2 | 16.6 | 15.2 |
| Reader 3 | 15.8 | 19.1 |
Collected over All Adverse Events (AEs) were collected from administration of investigational medicinal product (IMP) up to the 72 hours post injection regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sonazoid™ | 0/218 (0%) | 0/218 (0%) | 0/218 (0%) |
| SonoVue® | 0/206 (0%) | 0/206 (0%) | 0/206 (0%) |
Analysis was performed on safety analysis set that included all enrolled participants who received either Sonazoid™ or SonoVue.
| Age, Continuous(years) | Sonazoid™ | SonoVue® | Total |
|---|---|---|---|
| Mean | 54.5 ± 12.61 | 52.2 ± 13.77 | 53.4 ± 13.22 |
| Sex: Female, Male(Participants) | Sonazoid™ | SonoVue® | Total |
|---|---|---|---|
| Female | 81 | 81 | 162 |
| Male | 137 | 125 | 262 |
| Race (NIH/OMB)(Participants) | Sonazoid™ | SonoVue® | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 218 | 206 | 424 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
Ran from May 2014 to primary completion in Apr 2015, 10 months.
Results were first posted in Aug 2018, 3 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sonazoid